Empaveli: payments to doctors
Payments that named Empaveli as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 3,564
- Transactions
- 5,970
- Average per transaction
- $206
The per-transaction average — $206 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,564 providers the average total is $346, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | $1,194,930 | 96.9% |
| Swedish Orphan Biovitrum AB | $33,005 | 2.7% |
| SOBI, Inc | $4,713 | 0.4% |